~~<i id='8397E1996C'><strike id='8397E1996C'><tt id='8397E1996C'><pre id='8397E1996C'></pre></tt></strike></i>~~

Home» focus» leisure time

leisure time

author：explore 2025-10-02 13:04:20 Page View：1

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Orchard's therapy for neuron disease in children wins FDA approval
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

knowledge

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Here’s what’s in the FDA plan to include pregnant women in clinical trials

AdobeTheFDAhastakenabigstepinencouragingdrugcompaniestoincludepregnantwomeninclinicaltrials,issuinga

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

DarronCummings/APEliLillysaidFridaythatitwillacquireDermira,asmallbiotechdevelopingdrugsforchronicsk